1. NUC-1031 in biliary tract cancer: from bench to bedside and back?

   • Lenka N. C. Boyd
   • Godefridus J. Peters
   • Elisa Giovannetti

   Editorial 31 May 2020 Pages: 1011 - 1014

2. Assessing the translational value of pre-clinical studies for clinical response rate in oncology: an exploratory investigation of 42 FDA-approved small-molecule targeted anticancer drugs

   • Wenying Angela Liu
   • Li Yu
   • Barbara J. Brennan

   Review Article 18 May 2020 Pages: 1015 - 1027

   

3. Detection of trifluridine in tumors of patients with metastatic colorectal cancer treated with trifluridine/tipiracil

   • Yoshiaki Fujimoto
   • Ryota Nakanishi
   • Masaki Mori

   Original Article 22 April 2020 Pages: 1029 - 1038

   

4. In vivo assessment of the drug interaction between sorafenib and paracetamol in rats

   • Agnieszka Karbownik
   • Katarzyna Sobańska
   • Edyta Szałek

   Original Article Open access 11 May 2020 Pages: 1039 - 1048

   

5. The gut microbiota attenuates muscle wasting by regulating energy metabolism in chemotherapy-induced malnutrition rats

   • Haitao Chen
   • Chao Xu
   • Qinghua Yao

   Original Article 15 May 2020 Pages: 1049 - 1062

   

6. Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer

   • Mansi Arora
   • James M. Bogenberger
   • Mitesh J. Borad

   Original Article 21 May 2020 Pages: 1063 - 1078

   

7. MEK inhibition overcomes everolimus resistance in gastric cancer

   • Hongfang Liu
   • Yang Yao
   • Jing Li

   Original Article 22 May 2020 Pages: 1079 - 1087

   

8. A phase I dose-escalation study of the polyamine analog PG-11047 in patients with advanced solid tumors

   • Tracy Murray Stewart
   • Apurva A. Desai
   • Robert A. Casero Jr.

   Original Article 23 May 2020 Pages: 1089 - 1096

9. Anticancer effects of brusatol in nasopharyngeal carcinoma through suppression of the Akt/mTOR signaling pathway

   • Songbin Guo
   • Jinling Zhang
   • Zhenfeng Zhang

   Original Article 24 May 2020 Pages: 1097 - 1108

   

10. Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment

    • Ken Ogasawara
    • William B. Smith
    • Gopal Krishna

    Original Article 24 May 2020 Pages: 1109 - 1117

    

11. Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients

    • Natsumi Matsumoto
    • Yutaro Kubota
    • Ken-ichi Fujita

    Original Article 26 May 2020 Pages: 1119 - 1128

    

12. Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents

    • Guangan He
    • Xiaolei Xie
    • Zahid H. Siddik

    Original Article 28 May 2020 Pages: 1129 - 1140

    

13. Exposure–response analysis of endoxifen serum concentrations in early-breast cancer

    • Anabel Beatriz Sanchez-Spitman
    • Dirk-Jan A. R. Moes
    • Henk-Jan Guchelaar

    Original Article Open access 29 May 2020 Pages: 1141 - 1152

    

14. Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug

    • Mandy Juarez
    • Alejandro Schcolnik-Cabrera
    • Alfonso Duenas-Gonzalez

    Original Article 30 May 2020 Pages: 1153 - 1163

    

15. In vitro drug sensitivity (IDS) of patient-derived primary osteosarcoma cells as an early predictor of the clinical outcomes of osteosarcoma patients

    • Jeerawan Klangjorhor
    • Areerak Phanphaisarn
    • Dumnoensun Pruksakorn

    Original Article 31 May 2020 Pages: 1165 - 1176

    

16. CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model

    • J. H. Azambuja
    • R. S. Schuh
    • E. Braganhol

    Short Communication 16 May 2020 Pages: 1177 - 1182

    

17. Expression of Concern: shRNA-mediated silencing of ZFX attenuated the proliferation of breast cancer cells

    • Hongjian Yang
    • Yue Lu
    • Zhiqiang Ling

    Expression of Concern 10 April 2020 Pages: 1183 - 1183